Aristotle University Of Thessaloniki (AUTH)
Άξονας οστεοπροτεγερίνης/RANKL και αγγειακές επασβεστώσεις σε ασθενείς με χρόνια νεφρική νόσο σταδίου 5 σε χρόνια περιοδική αιμοκάθαρση
Abstract
dc:descriptionDespite the knowledge acquired over the last two decades, cardiovascular disease remains a serious health issue and the main cause of death in patients with chronic kidney disease, especially in those who are under renal replacement therapy (RRT). Vascular and cardiac valve calcifications occur very often in patients under RRT and in a higher degree than in general population patients and contribute to their cardiovascular disease. The observed vascular calcifications in CKD patients consist of two types, the atherosclerotic and the arteriosclerotic type. Atherosclerosis is characterized by calcification within the atherosclerotic plaque in the intima layer of the vessel wall, whereas arteriosclerosis is characterized by calcification of the medial layer of the vessel wall, which leads to loss of its elasticity and an increase in peripheral resistance. Many factors contribute to the pathogenesis of vascular calcifications, both traditional ones like older age, hypertension, diabetes mellitus, BMI, smoking and dyslipidemia, as well as non-traditional ones, which are a result of the chronic kidney disease and uremic milieu of these patients, like calcium and phosphate disorders, chronic inflammation, oxidative stress, duration of dialysis, bone metabolism disorders and the observed imbalance between inducers and inhibitors of ectopic calcifications. Vascular calcification is no longer considered as a passive precipitation of calcium and phosphate salts, but an active and highly regulated enzymatic process, where vascular smooth muscle cells are transdifferentiated to osteoblastic like cells, producing bone proteins and leading to osteogenesis of the vascular wall. Mineral bone disorders, as well as the observed change of other regulating factors’ function (fetuin-A, MGP, pyrophosphate, klotho, vitamin D, parathormone, the OPG/RANK/RANKL system) contribute to the appearance of vascular calcifications. Bone metabolism disorders (high bone turn over, low bone turn over) have been also correlated with the presence of cardiovascular calcifications, pointing out similar pathophysiological pathways leading to the appearance of these conditions, where the OPG/RANK/RANKL system seems to play an important role, acting as the binding link between the bone and the vessels. The aim of this study was to estimate the associations of OPG, RANKL and their ratio OPG/RANKL – which could also be used as a bone metabolism biomarker – with vascular and cardiac valve calcifications in end stage renal disease patients in hemodialysis. 80 ESRD patients under chronic hemodialysis were included in the study. Serum OPG and RANKL levels were estimated with the use of anosoenzymatic method (ELISA). The presence and severity of vascular calcifications was assessed with the use of plain hands and pelvic x-rays, which revealed radial, digital and inguinofemoral calcifications representing medial arterial calcification, and also with the use of lateral lumbar spine x-rays, which revealed abdominal aorta calcifications, representing intima calcification. The presence of cardiac valve calcifications was estimated with the use of transthoracic echocardiogram. Depending on the x-rays results and the calcification scores, patients were divided in the following categories: (1) Kauppila 1 – patients with abdominal aorta calcification score 0-4, (2) Kauppila 2 – patients with abdominal aorta calcification score 5-24, (3) Adragao 1 – patients with medial arterial calcification score 0-2, (4) Adragao 2 – patients with medial artery calcification score 3-8. Patients with Kauppila 2 or/and Adragao 2 scores were considered as having severe vascular calcifications, thus leading to the creation of other two categories. The first one was the low calcification score and low cardiovascular risk category, which consisted of patients with Kauppila 1 and Aragao 1 scores. The second one was the high calcification score and high cardiovascular risk category, which consisted of patients with severe vascular calcifications (Kauppila 2 or/and Adragao 2). Associations between serum OPG and RANKL levels and the OPG/RANKL ratio with age, duration of dialysis, gender, smoking, body mass index (BMI), dialysis method, presence of DM, hypertension, coronary artery disease, atrial fibrillation, cerebrovascular accident, peripheral artery and cardiovascular disease, prescribed therapeutic treatment, laboratory parameters (calcium, phosphate and magnesium levels, alkaline phosphatase, parathormone, albumin), lipids (cholesterol and triglycerides) and CRP were evaluated. Multivariate linear regression analysis was then performed to estimate the significance of the positive associations between some of these variables and the above-mentioned factors. Serum OPG levels were positively associated with age (p < 0.001, r = 0.56), duration of dialysis (p = 0.002, r = 0.338), the presence of DM (p = 0.041), history of atrial fibrillation (p = 0.010), CVA (p = 0.046), peripheral arterial and cardiovascular disease (p = 0.001, p = 0.003) and with the use of statins and anti-platelet agents (p = 0.002, p = 0.010). They were also associated with the HD method applied (patients who were on OLHDF had statistically significant lower OPG levels, p = 0.048). There weren’t any statistically significant associations with gender, tobacco use, hypertension and serum lipids. Serum RANKL levels did not show any associations with any of the clinical and laboratory parameters of the study population, whereas OPG/RANKL ratio was associated with age (p = 0.014, r = 0.278), duration of dialysis (p = 0.018, r = 0.267), the HD method (lower OPG/RANKL values in patients on OLHDF, p = 0.035) and with tobacco use (patients who were smoking had lower OPG/RANKL values, which could be the reason behind the correlation of smoking with osteoporosis, p = 0.033). The OPG/RANKL ratio was also negatively associated with serum magnesium levels (p = 0.048, r = - 0.229), a result though that needs further investigation, since animal and general population studies have so far given different information, associating low serum magnesium levels with lower OPG/RANKL values and with an increase in bone resorption and osteoporosis. The variables that retained their statistical significance after the linear regression analysis concerning serum OPG levels were age (p < 0.001), time on dialysis (p < 0.001) and the HD method (p = 0.029), whereas the ones concerning the OPG/RANKL ratio were age and time on dialysis (p = 0.006, p = 0.008). Associations between cardiovascular calcifications and the above-mentioned clinical and laboratory parameters were also evaluated. Older age, diabetes mellitus and the history of coronary artery disease, peripheral artery and cardiovascular disease were all positively associated with the presence and severity of cardiac valve, abdominal aorta and medial arterial calcifications. Hypertension was positively associated with aortic valve and abdominal aorta calcifications, whereas elevated BMI with mitral valve and medial arterial calcifications. The use of high flux dialyzer was significantly correlated with the lower incidence of mitral valve calcification, as was also the use of non-calcium containing phosphate binders. Another interesting result was the strong positive association between lower serum magnesium levels and the increased incidence of both cardiac valve calcifications, whereas duration of dialysis and serum phosphate levels were correlated with medial arterial calcifications. Associations of serum OPG and RANKL levels and of the OPG/RANKL ratio with the presence and severity of cardiovascular calcifications were also estimated. Serum OPG levels were strongly and positively associated with both cardiac valve calcifications, abdominal aorta and medial arterial calcifications, as well as with the increased calcification score and increased cardiovascular risk (p < 0.001 in all categories). On the contrary, serum RANKL levels did not show any statistically significant correlations with cardiovascular calcifications, whereas OPG/RANKL ratio was positively correlated with aortic valve calcification (p = 0.011), abdominal aorta calcification (p = 0.022) and with the increased calcification score (p = 0.014), correlations though that are most likely a result of OPG’s strong association with these variables. Multivariate stepwise logistic regression analysis was then performed to examine the prognostic significance and positive associations of serum osteoprotegerin levels in predicting the presence and severity of cardiac valve and vascular calcifications, after adjustment to other risk factors. Older age, presence of hypertension and DM, history of coronary artery disease, BMI and serum phosphate and magnesium levels were the risk factors included in the regression analysis. Aortic valve calcification was positively associated with serum OPG levels (p = 0.005), hypertension (p = 0.044), as well as with lower serum magnesium levels (p = 0.022) at the end of the multivariate analysis. Serum magnesium levels were also the only variable that retained its significance predicting the presence of mitral valve calcification (p = 0.010), whereas the variables that were associated with calcification of both cardiac valves were the presence of DM (p = 0.033) and serum magnesium levels (p = 0.043). Serum OPG levels (p = 0.002) and an elevated BMI (p = 0.009) were positively associated with the presence and severity of medial arterial calcifications, whereas in the case of abdominal aorta calcification and increased calcification score, the only variable that retained its statistical and prognostic significance at the end of the regression analysis were serum OPG levels (p = 0.001 and p = 0.003 respectively). Patients were also divided in two groups according to their OPG values and their relative risk concerning the presence of cardiovascular calcifications was then estimated. Compared to the group of patients with serum OPG levels equal and below the median value (≤ 44,68 pmol/L), patients with serum OPG levels above the median value (≥ 44,69 pmol/L) had 56% and 54% increased possibility for the presence of aortic and mitral valve calcification respectively, 154% and 88% increased possibility for the appearance of severe abdominal aorta (5-24) and medial arterial (3-8) calcifications respectively, as well as 188% increased possibility for the presence of a high calcification score and a high cardiovascular risk. Five years after the initiation of the study, 47 of the 80 patients who were included, had new x-rays done. The presence and severity of vascular calcifications was evaluated and patients were again categorized in low and high calcification score groups. With the use of a cox regression analysis model, age, serum OPG values and hypertension were included as variables predicting the progression of AACs, whereas BMI was used instead of hypertension in the regression analysis of medial arterial calcifications. Despite the strong positive association that OPG had with the presence of VCs upon enrollment, it was not associated with their progression. On the contrary, age had a positive association with the progression of AACs and BMI with the progression of medial arterial calcifications. In conclusion, serum OPG levels were positively correlated with age, duration of dialysis, diabetes mellitus and cardiovascular disease, conditions who are all characterized by a status of chronic inflammation and endothelial malfunction. The statistically significant reduction of OPG levels in patients who were on OLHDF, could probably then be the result of a more efficient dialysis and an improvement of the uremic milieu and chronic inflammation in these patients. Serum RANKL levels did not show any significant associations with any of the parameters examined, whereas OPG/RANKL ratio was positively associated with age, smoking and duration of dialysis. The observed positive association between cardiovascular calcifications and the history of coronary artery and peripheral artery disease, certifies the strong value of using plain hands, pelvis and lateral lumbar spine x-rays, as well as the transthoracic echocardiogram, in predicting both the presence of cardiovascular calcifications and also stratifying the patients into low and increased cardiovascular risk categories. Serum OPG levels were strongly associated with cardiac valve and vascular calcifications and this association retained its significance after adjustment to other risk factors, including age and DM. OPG was actually the only variable that was positively associated with the presence and severity of abdominal aorta calcifications and with the increased calcification score in the end of the regression analysis, a result that proves its strong prognostic significance concerning the presence of cardiovascular calcifications in ESRD patients in hemodialysis, especially in younger ones. The observed though lack of association of OPG with the progression of VCs, suggests that OPG appears mostly as a marker of vascular calcification onset rather than its progression and highlights the need to clarify its exact actions and functions. Serum RANKL levels did not exhibit any statistically significant associations with cardiovascular calcifications, hence its use as a prognostic marker for their appearance cannot be supported at the moment. The associations that the OPG/RANKL ratio had with the cardiovascular calcifications seem to be a result of the strong association serum OPG levels had with them and not from the ratio itself, pointing out the need for further studies to prove its use as a bone metabolism biomarker and to also clarify its associations with cardiovascular calcifications.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Spartalis, Michalis
- Σπαρτάλης, Μιχάλης
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54164